187834-88-4

Usage

Uses

Used in Pharmaceutical Research:
1-BOC-ISONIPECOTIC ACID HYDRAZIDE is used as a reagent for the synthesis of complex compounds in pharmaceutical research. Its active hydrazide group enables it to engage in multiple reactions, making it a valuable component in the development of new drugs and therapeutic agents.
Used in Chemical Synthesis:
1-BOC-ISONIPECOTIC ACID HYDRAZIDE is used as a key intermediate in the synthesis of various chemical compounds. Its ability to participate in condensation, coupling, and reduction reactions allows it to be a crucial component in the creation of new molecules with potential applications in various industries.
Used in Scientific Research:
1-BOC-ISONIPECOTIC ACID HYDRAZIDE is used as a research tool in various scientific fields. Its unique chemical properties and reactivity make it an interesting subject for study, potentially leading to new discoveries and advancements in the understanding of chemical reactions and processes.

InChI:InChI=1/C11H21N3O3/c1-11(2,3)17-10(16)14-6-4-8(5-7-14)9(15)13-12/h8H,4-7,12H2,1-3H3,(H,13,15)

Upstream product

• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 64269-79-0 Carbonyldiimidazole 
• 1126-09-6 4-carbethoxypiperidine 
• 124443-68-1 1-tert-Butyl 4-methyl piperidine-1,4-dicarboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 2971-79-1 isonipecotic acid methyl ester 
• 293744-38-4 tert-butyl 4-(1H-imindazole-1-carbonyl)piperidine-1-carboxylate 
• 142851-03-4 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate 

Downstream Products

• 280110-70-5 4-(5-phenyl-[1,3,4]oxadiazol-2-yl)-piperidine-1-carboxylic acid tert-butyl ester 
• 280110-69-2 4-(5-methyl-[1,3,4]oxadiazol-2-yl)-piperidine-1-carboxylic acid tert-butyl ester 
• 1205637-02-0 tert-butyl 4-[3-(4-chlorophenyl)-1H-1,2,4-triazol-5-yl]piperidine-1-carboxylate 
• 1312793-98-8 tert-butyl 4-(2-(3-cyclopentyloxy-4-methoxybenzoyl)hydrazinecarbonyl)piperidine-1-carboxylate 
• 1312793-99-9 2-(3-cyclopentyloxy-4-methoxyphenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole 
• 1312794-00-5 tert-butyl 4-(5-(3-(cyclopentyloxy)-4-methoxyphenyl)-1,3,4-thiadiazol-2-yl)piperidine-1-carboxylate 
• 1312794-01-6 2-(3-cyclopentyloxy-4-methoxyphenyl)-5-(piperidin-4-yl)-1,3,4-thiadiazole 
• 1401729-06-3 tert-butyl 4-(2-(4-((2-ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)benzoyl)hydrazinecarbonyl)piperidine-1-carboxylate 
• 1401728-56-0 2-(4-((2-Ethyl-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)-phenyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole 
• 1419075-88-9 4-[1,3,4]oxadiazol-2-yl-piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT4Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer's Disease

A series of oxadiazole derivatives were synthesized and evaluated as 5-hydroxytryptamine-4 receptor (5-HT4R) partial agonists for the treatment of cognitive deficits associated with Alzheimer's disease. Starting from a reported 5-HT4R antagonist, a systematic structure-activity relationship was conducted, which led to the discovery of potent and selective 5-HT4R partial agonist 1-isopropyl-3-{5-[1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole oxalate (Usmarapride, 12l). It showed balanced physicochemical-pharmacokinetic properties with robust nonclinical efficacy in cognition models. It also showed disease-modifying potential, as it increased neuroprotective soluble amyloid precursor protein alpha levels, and dose-dependent target engagement and correlation of efficacy with oral exposures. Phase 1 clinical studies have been completed and projected efficacious concentration was achieved without any major safety concerns. Phase 2 enabling long-term safety studies have been completed with no concerns for further development.

Reinvestigation of the structure-activity relationships of isoniazid

Isoniazid (INH) remains a cornerstone for treatment of drug susceptible tuberculosis (TB), yet the quantitative structure-activity relationships for INH are not well documented in the literature. In this paper, we have evaluated a systematic series of INH analogs against contemporary Mycobacterium tuberculosis strains from different lineages and a few non-tuberculous mycobacteria (NTM). Deletion of the pyridyl nitrogen atom, isomerization of the pyridine nitrogen to other positions, replacement of the pyridine ring with isosteric heterocycles, and modification of the hydrazide moiety of INH abolishes antitubercular activity. Similarly, substitution of the pyridine ring at the 3-position is not tolerated while substitution at the 2-position is permitted with 2-methyl-INH 9 displaying antimycobacterial activity comparable to INH. To assess the specific activity of this series of INH analogs against mycobacteria, we assayed them against a panel of gram-positive and gram-negative bacteria, as well as a few fungi. As expected INH and its analogs display a narrow spectrum of activity and are inactive against all non-mycobacterial strains evaluated, except for 4, which has modest inhibitory activity against Cryptococcus neoformans. Our findings provide an updated analysis of the structure-activity relationship of INH that we hope will serve as useful resource for the community.

TBSOTf-promoted versatile N-formylation using DMF at room temperature

Hydrazides and amines were N-formylated by DMF in the presence of tert-butyldimethylsilyl triflate (TBSOTf) at room temperature, in good to excellent yields.

Discovery of a 3,4,5-trisubstituted-1,2,4-triazole agonist with high affinity and selectivity at the somatostatin subtype-4 (sst4) receptor

A series of compounds containing a 1,2,4-triazole moiety were synthesized, targeting the somatostatin receptor subtype-4 (sst4). Compounds were developed in which the Phe6/Phe7/Phe11, Trp8, and Lys9 mimetic groups were interchanged at positions 3, 4, and 5 of the 1,2,4-triazole ring. The 1,2,4-triazoles containing an 2-(imidazol-4-yl)ethyl substituent at position-3 demonstrated moderate binding affinity at sst4. 1,2,4-Triazoles containing an (indol-3-yl)methyl substituent at position-5 lacked affinity at sst4. The 1,2,4-triazoles containing an aminopropyl group at position-4 showed enhanced binding affinity compared to the 3-position. One compound with an 3-(imidazol-4-yl)propyl group at position-4 (compound 44) imparted high affinity and selectivity at sst4 (sst2A = >10000 nM; sst4 = 19 nM), acting as an agonist (EC50 = 6.8 nM). Docking 44 into a model-built structure of sst4 pointed to differences in its binding versus the other low-affinity compounds and was also in line with one of the two previously reported binding modes. A virtual screening (VS) experiment, employing two separate docking algorithms, was able to score 44 among the top-ranked poses. In summary, compound 44 represents a novel and promising lead structure towards the development of a clinically viable sst4 agonist for the treatment of conditions ranging from Alzheimer's disease to chronic pain.

ANTIBIOTIC COMPOUNDS

The present invention relates to antibiotic compounds of formula (I), to compositions containing these compounds and to methods of treating bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Gram-positive and/or Gram-negative bacteria, and in particular in the treatment of infection with, and diseases caused by, Neisseria gonorrhoeae.

Triazole alcohol antifungal compound with piperidine oxadiazole side chain and preparation method for compound and application of compound

The invention relates to the medical technical field and provides 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-(piperidine oxadiazole side chain substituted)-2-propanol compounds in one category. The compound comprises cis-trans-isomers thereof and any mixtures in the forms or pharmaceutical salts thereof. The chemical structural formula of the compound is represented by a formula (I). The invention further provides a preparation method for the compound and an application of the compound in preparing antifungal drugs. From an antifungal experiment, the compound provided by the invention has a very strong antifungal effect on various superficial fungi and deep fungi. Compared with existing clinically applied antifungal drugs such as fluconazole, the compound has the advantages of being efficient, low in toxicity and wide in antifungal spectrum, has relatively good activity on fluconazole drug-resistant bacteria and can be used for preparing antifungal drugs. The formula is shown in the description.

SUBSTITUTED INDAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are methods for treating and preventing malaria and/or Babesiosis, the methods comprising administering an effective amount of Indazole Compounds having the formulas: (I)[Formula (I) should be inserted here] or (II)[Formula (II) should be inserted here] wherein R1, R2, R3 and Y are as defined herein.

FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS

The disclosure provides novel chemical compounds represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof. The compounds can be used as an inhibitor of Trk and are useful in the treatment of pain, cancer, inflammation, neurodegenerative disease and certain infectious diseases. In some compounds of Formula I, Q is —CH═CR3C(O)NR4R5, —C≡CC(O)NR4R5, or

Discovery of highly potent triazole antifungal agents with piperidine-oxadiazole side chains

Due to increasing incidence and mortality of invasive fungal infections, discovery and development of new generations of antifungal agents represents a challenging task. On the basis of our previously reported triazole-benzyloxypiperidinyl lead compound, a series of novel triazole antifungal agents containing piperidine-oxadiazole side chains were rationally designed and synthesized. Most of the target compounds showed excellent inhibitory activity against clinically important fungal pathogens. In particular, compounds 6g (MIC = 0.031 μg mL-1) and 11b (MIC = 0.016 μg mL-1) were highly active against Candida albicans including fluconazole-resistant strains. Moreover, they showed inhibitory activity against hyphal formation with low toxicity, which were promising leads for further development. This journal is

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.